Published in Women's Health Weekly, January 20th, 2005
Best known for its state-of-the-art, third-generation smallpox vaccine, Bavarian Nordic will utilize its patented MVA-BN vaccine vector in the development of these cancer vaccine-development programs.
"The combination of new and promising data from our earlier cancer projects combined with the strong safety profile of our MVA-BN technology has led us to expand our research in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly